243 related articles for article (PubMed ID: 33239914)
1. Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts.
Liu S; Liu F; Zhao M; Zhang J
Cancer Manag Res; 2020; 12():11803-11812. PubMed ID: 33239914
[TBL] [Abstract][Full Text] [Related]
2. Macrophage polarization contributes to the efficacy of an oncolytic HSV-1 targeting human uveal melanoma in a murine xenograft model.
Liu S; Zhang J; Fang S; Zhang Q; Zhu G; Tian Y; Zhao M; Liu F
Exp Eye Res; 2021 Jan; 202():108285. PubMed ID: 33039456
[TBL] [Abstract][Full Text] [Related]
3. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
Liu S; Zhang J; Fang S; Su X; Zhang Q; Zhu G; Zhu L; Zhao M; Liu F
Cancer Lett; 2020 Dec; 495():123-134. PubMed ID: 32946963
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinoma.
Liu H; Yuan SJ; Chen YT; Xie YB; Cui L; Yang WZ; Yang DX; Tian YT
World J Gastroenterol; 2013 Aug; 19(31):5138-43. PubMed ID: 23964149
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1.
Kim KJ; Moon D; Kong SJ; Lee YS; Yoo Y; Kim S; Kim C; Chon HJ; Kim JH; Choi KJ
Gene Ther; 2021 Apr; 28(3-4):186-198. PubMed ID: 33149278
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the immune effect of oHSV-1 therapy through TLR3 signaling in uveal melanoma.
Liu S; Li M; Sun F; Zhang J; Liu F
J Cancer Res Clin Oncol; 2023 Feb; 149(2):901-912. PubMed ID: 36030435
[TBL] [Abstract][Full Text] [Related]
9. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
10. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.
Malhotra S; Kim T; Zager J; Bennett J; Ebright M; D'Angelica M; Fong Y
Surgery; 2007 Apr; 141(4):520-9. PubMed ID: 17383529
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus thymidine kinase and granulocyte macrophage colony-stimulating factor combination gene therapy in a murine CT26 cell colon cancer model.
Lee KH; Piao H; Son BR; Heo DS; Kim NK; Kim ST
Cancer Gene Ther; 2004 Aug; 11(8):570-6. PubMed ID: 15232602
[TBL] [Abstract][Full Text] [Related]
13. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
[TBL] [Abstract][Full Text] [Related]
15. A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy.
Hu H; Zhang S; Cai L; Duan H; Li Y; Yang J; Wang Y; Liu B; Dong S; Fang Z; Liu B
Virol J; 2022 Apr; 19(1):74. PubMed ID: 35459242
[TBL] [Abstract][Full Text] [Related]
16. Combination Immunotherapy of Oncolytic Flu-Vectored Virus and Programmed Cell Death 1 Blockade Enhances Antitumor Activity in Hepatocellular Carcinoma.
Yu H; Sun F; Xu Y; Yang H; Tian C; Li C; Kang Y; Hao L; Yang P
Hum Gene Ther; 2024 Mar; 35(5-6):177-191. PubMed ID: 38386514
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
[TBL] [Abstract][Full Text] [Related]
18. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of the UL37 Deamidase Enhances Virus Replication and Spread of the HSV-1(VC2) Oncolytic Vaccine Strain and Secretion of GM-CSF.
Clark CM; Jambunathan N; Collantes TMA; Kousoulas KG
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851581
[TBL] [Abstract][Full Text] [Related]
20. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]